BLINDING TRACHOMA: PREVENTION WITH THE SAFE STRATEGY

2003 ◽  
Vol 69 (5_suppl_1) ◽  
pp. 18-23 ◽  
Author(s):  
SHEILA K. WEST
2013 ◽  
Vol 2013 ◽  
pp. 1-18 ◽  
Author(s):  
Diane K. Lavett ◽  
Van C. Lansingh ◽  
Marissa J. Carter ◽  
Kristen A. Eckert ◽  
Juan C. Silva

Since the inception of (the Global Elimination of Blinding Trachoma) GET 2020 in 1997 and the implementation of the SAFE strategy a year later, much progress has been made toward lowering the prevalence of trachoma worldwide with elimination of the disease in some countries. However, high recurrence of trichiasis after surgery, difficulty in controlling the reemergence of infection after mass distribution of azithromycin in some communities, the incomplete understanding of environment in relation to the disease, and the difficulty in establishing the prevalence of the disease in low endemic areas are some of the issues still facing completion of the GET 2020 goals. In this narrative review, literature was searched from 1998 to January 2013 in PubMed for original studies and reviews. Reasons for these ongoing problems are discussed, and several suggestions are made as avenues for exploration in relation to improving the SAFE strategy with emphasis on improving surgical quality and management of the mass treatment with antibiotics. In addition, more research needs to be done to better understand the approach to improve sanitation, hygiene, and environment. The main conclusion of this review is that scale-up is needed for all SAFE components, and more research should be generated from communities outside of Africa and Asia.


2003 ◽  
Vol 3 (6) ◽  
pp. 372-381 ◽  
Author(s):  
Hannah Kuper ◽  
Anthony W Solomon ◽  
John Buchan ◽  
Marcia Zondervan ◽  
Allen Foster ◽  
...  

The Lancet ◽  
2012 ◽  
Vol 380 (9836) ◽  
pp. 27-28 ◽  
Author(s):  
Paul Emerson ◽  
Martin Kollmann ◽  
Chad MacArthur ◽  
Simon Bush ◽  
Danny Haddad

2010 ◽  
Vol 17 (6) ◽  
pp. 360-365 ◽  
Author(s):  
Rajiv Khandekar ◽  
Harith Al Harthy ◽  
Saleh Al Harby ◽  
Saleh Al Hinai ◽  
Khalid Al Saadi ◽  
...  

2021 ◽  
Author(s):  
Salisu M. Muhammad ◽  
Evren Hincal ◽  
Bilgen Kaymakamzade ◽  
Nezihal Gokbulut

RSC Advances ◽  
2014 ◽  
Vol 4 (106) ◽  
pp. 61491-61502 ◽  
Author(s):  
Aurelio Salerno ◽  
Mar Fernández-Gutiérrez ◽  
Julio San Román del Barrio ◽  
Concepción Domingo Pascual

2017 ◽  
Vol 52 (1) ◽  
pp. 11-18 ◽  
Author(s):  
José Luis Revuelta-Herrero ◽  
Esther Chamorro-de-Vega ◽  
Carmen Guadalupe Rodríguez-González ◽  
Roberto Alonso ◽  
Ana Herranz-Alonso ◽  
...  

Background: Evidence about the use of dolutegravir (DTG) and rilpivirine (RPV) as an antiretroviral therapy (ART) in treatment-experienced patients is scarce. Objective: To explore the effectiveness, safety, and costs of switching to a DTG plus RPV regimen in this population. Methods: This observational, prospective study included all treatment-experienced patients who switched to DTG plus RPV between November 2014 and July 2016. Patients were excluded if resistance mutations to integrase inhibitors or RPV were found. The effectiveness endpoint was the proportion of patients who achieved virological suppression (viral load [VL] <50 copies/mL) at week 48 (W48). Safety (incidence of adverse events leading to discontinuation and laboratory abnormalities), adherence, and costs were analyzed. Results: A total of 35 patients were included, and 91.4% were virologically suppressed at baseline. Patients were treated with ART for a median of 14 years (interquartile range = 7-20). At W48, 91.4% of patients were virologically suppressed (95% CI = 77.0-98.2). Two of the 3 patients not suppressed at baseline achieved undetectable VL at W48, and 2 patients discontinued DTG plus RPV (intolerance and a drug-drug interaction). None of the virologically suppressed patients at baseline showed virological rebound through W48. There were no significant changes in lipid, liver, and renal profiles. The proportion of patients with an ART adherence >90% increased from 65.6% to 93.8% ( P = 0.004). The annual per-patient ART costs dropped by €665 ( P = 0.265). Conclusions: Switching to DTG plus RPV seems to be an effective and safe strategy. Significant improvements in patients’ adherence and costs were achieved.


2013 ◽  
Vol 47 (3) ◽  
pp. 232-233 ◽  
Author(s):  
Nawfal Fejjal ◽  
Jawad Hafidi ◽  
Redouane Belmir ◽  
Samir El Mazouz ◽  
Abdellah Abbassi ◽  
...  

2010 ◽  
Vol 68 (5) ◽  
pp. 775-777
Author(s):  
Jair Leopoldo Raso ◽  
Rogério Zenóbio Darwich ◽  
Francisco de Lucca Jr ◽  
Romeu Valle Santana ◽  
Marco Túlio Tanure ◽  
...  

Cervical clot is one of the complications of endarterectomy. This risk may be higher in patients using aspirin or clopidogrel. On the other hand, stroke may occur if the medication is interrupted before surgery. We carried out a prospective study of 124 endarterectomies in 119 patients in which aspirin or clopidogrel was stopped and a bridge-therapy with enoxaparin was administered preoperatively. There was no case of stroke during the period of the bridge-therapy. One patient developed cervical clot (0.8%) in the fifth postoperative day. Mortality rate in this series was 0.8%. There was no complication directly related to the use of enoxaparin. Bridge-therapy with low molecular weight heparin is a safe strategy for patients elected for endarterectomy


Sign in / Sign up

Export Citation Format

Share Document